

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Clostridia Difficile Diarrhea

Enoch Lule

*Medical Center Of Central Georgia
USA*

1. Introduction

The term antibiotic associated diarrhea is usually reserved for diarrhea caused by infection with the organism *Clostridia Difficile*. Infection is thought to take place after the normal intestinal flora is altered by antibiotic use allowing for proliferation of *Clostridia Difficile*. Worryingly, the incidence and severity of illness caused by *Clostridia Difficile* is on the increase.

2. Pathophysiology

Clostridia difficile is a gram positive, spore forming anaerobic bacilli¹ Infection occurs when the organism is ingested. Though initially thought of as a nosocomial infection, community acquired *clostridia difficile* infection is increasingly recognized.²

Clostridia Difficile produces a variety of toxins, toxin A (enterotoxin) and B (cytotoxin) are the toxins most frequently linked to disease. They cause inflammation and disrupt cell cytoskeleton synthesis leading to colonic cell disruption.^{3,4,5} A new strain, termed NAP1 or BI or 027 (depending on the technique used to identify it) was identified in the early 2000s the cause of selected outbreaks. This strain of *clostridia difficile* is associated with clinically more severe disease, innate resistance to quinolones and higher amounts of toxin production.⁶

3. Epidemiology

Clostridia difficile infection was linked to the development of pseudomembranous colitis in the 70's.⁷ Initial cases were mostly linked to clindamycin but since then the range antibiotics linked with development of *Clostridia Difficile* has widened and cephalosporins and floroquinolones are thought to be the major causes.⁸

Though less often thought of as a cause of diarrhea in developing countries, pathogenic *C. Difficile* has been noted in South Africa⁹ and India.¹⁰

The incidence rate of *C. Difficile* infection in the US was about 30 to 40 cases per hundred thousand.¹¹

One research group noted an increasing rate of colectomies following *C. Difficile* infection.¹² Canadian authors noted a four fold increase in background prevalence of *C. Difficile* between when the period before 2002 was compared to 2003.¹³

4. Clinical presentation

Presentation may range from asymptomatic carrier state¹⁴ to fulminant colitis.¹⁵

Symptomatic patients typically present with watery diarrhea and lower abdominal pain.¹⁶ Severe diarrhea with leucocytosis, fever, abdominal pain and distention occurs in the severely ill^{16,17}. Surgical management with colectomy may be required in severe cases¹⁸. *C. Difficile* colitis was increasingly listed as the cause of death in an English population.¹⁹ Rises in white cell count to above 30,000 or a doubling of serum creatinine have been suggested as harbingers complicated disease.²⁰

5. Diagnosis

C. Difficile diagnosis is usually done with laboratory testing in a patient suspected to be having the infection.

One of the most sensitive and specific tests available is the cell cytotoxicity assay, which had a sensitivity of 98% and specificity of 99% when compared to clinical and laboratory criteria.²¹ This test is unfortunately technically demanding and may not be the first choice of many laboratories.

Many laboratories will use EIAs for detection of toxin A and B. These tests are insensitive when compared to cell culture or cytotoxicity assay but they are cheaper and produce results in hours rather than days.²² Due to the lower positive predictive value of these tests a 2 step approach with a sensitive screening test followed by confirmation by culture or cell cytotoxicity may be appropriate.²³

Testing for glutamate dehydrogenase, an enzyme produced by *C. Difficile* is sensitive (96 to 100%)²⁴, cheap, and rapid but it only detects presence of organism rather than toxin production.

Though its usually unnecessary, direct visualization of colitis by endoscopy is virtually diagnostic as they are few other infections that would cause pseudomembrane formation.²⁵ Endoscopy carries the risk of perforation in fulminant colitis.

6. Treatment

First line therapy for *C. Difficile* infection has long been considered to be a choice between metronidazole or vancomycin. Resolution of disease was seen in over 90% of patients taking a 10 day course of either therapy.²⁶

More recently, metronidazole has been associated with therapeutic failure rates as high as 50 percent if persistence of disease and recurrence are combined.²⁷ That said, oral metronidazole at a dose of 500mg, three times daily for ten to fourteen days remains the initial recommended therapy for mild disease.²⁸ Oral or rectal vancomycin (500mg four times a day) is recommended for more severe disease.²⁸ Patients who cannot tolerate oral therapy may be treated with intravenous metronidazole.²⁹

Up to 25% of patients may have recurrent infection¹⁶ believed to occur because of germination of spores or ingestion of new spores.

Many approaches have been taken to recurrent symptomatic *C Difficile* infection. A tapered or pulsed course of oral vancomycin may reduce recurrence rates³⁰.

Other approaches include fecal transplants³¹, immunization against *C. difficile* toxins³², cholestyramine³³, rifampin³⁴ or probiotics³⁵. There isn't sufficient data to recommend any of these approaches.

Recently fidaxomicin (200 mg oral, twice daily for ten days), a macrolide antibiotic, was shown to be non inferior to vancomycin.³⁶ During the trial referenced, patients were noted to have a lower recurrence rate when they were treated using fidaxomicin rather than vancomycin (13.3% vs. 24.0%)

7. Prevention

Judicious use of antibiotics has been shown to reduce the rates of *C. difficile* infection.^{37, 38} Washing hands with soap and water, using gloves when touching patients and use of disposable thermometers have been recommended as control measures with good quality evidence of efficacy.³⁹ Alcohol hand washing gels are not effective in preventing disease spread.⁴⁰

8. References


- [1] Ryan KJ, Ray CG (editors) (2004). *Sherris Medical Microbiology* (4th ed.). McGraw Hill. pp. 322-4. ISBN 0-8385-8529-9.
- [2] Epidemiology of community-acquired *Clostridium difficile*-associated diarrhea. Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R. *J Infect Dis*. 1994 Jan;169(1):127-33.
- [3] Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories K. Glucosylation of Rho proteins by *Clostridium difficile* toxin B. *Nature*. 1995;375(6531):500.
- [4] *Clostridium difficile* toxin A. Interactions with mucus and early sequential histopathologic effects in rabbit small intestine. Lima AA, Innes DJ Jr, Chadee K, Lysterly DM, Wilkins TD, Guerrant RL. *Lab Invest*. 1989;61(4):419.
- [5] *Clostridium difficile* toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Ng J, Hirota SA, Gross O, Li Y, Ulke-Lemee A, Potentier MS, Schenck LP, Vilaysane A, Seamone ME, Feng H, Armstrong GD, Tschopp J, Macdonald JA, Muruve DA, Beck PL. *Gastroenterology*. 2010 Aug;139(2):542-52, 552.e1-3. Epub 2010 Apr 13.
- [6] Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. *Lancet*. 2005;366(9491):1079
- [7] Role of *Clostridium difficile* in antibiotic-associated pseudomembranous colitis. Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB. *Gastroenterology*. 1978;75(5):778.
- [8] Narrative review: the new epidemic of *Clostridium difficile*-associated enteric disease. Bartlett JG *Ann Intern Med*. 2006;145(10):758.
- [9] PCR detection of *Clostridium difficile* triose phosphate isomerase (tpi), toxin A (tcdA), toxin B (tcdB), binary toxin (cdtA, cdtB), and tcdC genes in Vhembe District, South

- Africa. Samie A, Obi CL, Franasiak J, Archbald-Pannone L, Bessong PO, Alcantara-Warren C, Guerrant RL. Am J Trop Med Hyg. 2008 Apr;78(4):577-85.
- [10] Dhawan B, Chaudhry R, Sharma N. Incidence of *Clostridium difficile* infection: a prospective study in an Indian hospital. J Hosp Infect. 1999;43:275-280. Abstract
- [11] McDonald LC, Owings M, Jernigan JB. *Clostridium difficile* infection in patients discharged from US short-stay hospitals, 1996 to 2003. Emerg Infect Dis 2006;12:409-415 Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN.
- [12] Increasing prevalence and severity of *Clostridium difficile* colitis in hospitalized patients in the United States. Arch Surg. 2007;142:624-631; discussion 631.
- [13] Pepin J, Valiquette L, Alary ME, et al. *Clostridium difficile*-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466-472
- [14] Nosocomial acquisition of *Clostridium difficile* infection. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. N Engl J Med. 1989;320(4):204.
- [15] Severe *Clostridium difficile* colitis. Rubin MS, Bodenstein LE, Kent KC. Dis Colon Rectum. 1995;38(4):350.
- [16] *Clostridium difficile* Colitis. Ciaran P. Kelly, Charalabos Pothoulakis, and J. Thomas LaMont. N Engl J Med 1994; 330:257-26
- [17] Leukocytosis as a harbinger and surrogate marker of *Clostridium difficile* infection in hospitalized patients with diarrhea. Bulusu M, Narayan S, Shetler K, Triadafilopoulos G. Am J Gastroenterol. 2000;95(11):3137.
- [18] Fulminant *Clostridium difficile*: An Underappreciated and Increasing Cause of Death and Complications. Ramsey M. Dallal, Brian G. Harbrecht, Arthur J. Boujoukas, Carl A. Sirio, Linda M. Farkas Kenneth K. Lee, Richard L. Simmons, Ann Surg. 2002 March; 235(3): 363-372.
- [19] United Kingdom national statistics. Newport, United Kingdom: Office for National Statistics, UK Statistics Authority. (Accessed October 6, 2008, at <http://www.statistics.gov.uk>.)
- [20] Predictors of Serious Complications Due to *Clostridium difficile* Infection. D. Gujja; F. K. Friedenberg. Alimentary Pharmacology & Therapeutics. 2009;29(6):635-642.
- [21] Connor D, Hynes P, Cormican M, Collins E, Corbett-Feeney G, Cassidy M. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of *Clostridium difficile*-associated diarrhea. J Clin Microbiol 2001;39:2846-9.
- [22] Clinical Recognition and Diagnosis of *Clostridium difficile* Infection. John G. Bartlett and Dale N. Gerding. Clin Infect Dis. (2008) 46 (Supplement 1): S12-S18. doi: 10.1086/521863
- [23] Planche T, Aghaizu A, Holiman R, et al. Diagnosis of *Clostridium difficile* infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008;8:777-784
- [24] Ticehurst JR, Aird DZ, Dam LM, Borek AP, Hargrove JT, Carroll KC. Effective detection of toxigenic *Clostridium difficile* by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006;44:1145-9.

- [25] Kawamoto S, Horton KM, Fishman EK. Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. *Radiographics* 1999;19:887-97.
- [26] Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of *Clostridium difficile*-associated diarrhea [published correction appears in *Clin Infect Dis* 1996;23:423]. *Clin Infect Dis*. 1996;22:813-8.
- [27] Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of *Clostridium difficile* colitis with metronidazole. *Clin Infect Dis* 2005;40:1586-1590
- [28] Shea-idsa guideline. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Stuart H. Cohen, Dale N. Gerding, Stuart Johnson, Ciaran P. Kelly, Vivian G. Loo, L. Clifford McDonald, Jacques Pepin, Mark H. Wilcox. *Infect Control Hosp Epidemiol* 2010; 31(5):000-000
- [29] Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to *Clostridium difficile*. *Gut* 1986;27:1169-1172
- [30] McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent *Clostridium difficile* disease. *Am J Gastroenterol* 2002;97:1769-1775
- [31] Aas J, Gessert CE, Bakken JS. Recurrent *Clostridium difficile* colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. *Clin Infect Dis* 2003;36:580-585 Tedesco FJ. Treatment of recurrent antibiotic-associated pseudomembranous colitis. *Am J Gastroenterol* 1982;77:220-221
- [32] Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by *Clostridium difficile* toxin. *J Pediatr* 1991;118:633-637
- [33] Zimmerman MJ, Bak A, Sutherland LR. Treatment of *Clostridium difficile* infection. *Aliment Pharmacol Ther* 1997;11:1003-1012
- [34] Buggy BP, Fekety R, Silva J Jr. Therapy of relapsing *Clostridium difficile*-associated diarrhea and colitis with the combination of vancomycin and rifampin. *J Clin Gastroenterol* 1987;9:155-159
- [35] Probiotics for treatment of *Clostridium difficile*-associated colitis in adults. Anjana Pillai, Richard L Nelson. Intervention review, The Cochrane Library. DOI: 10.1002/14651858.CD004611.pub2
- [36] Fidaxomicin versus Vancomycin for *Clostridium difficile* Infection. Thomas J. Louie, Mark A. Miller, Kathleen M. Mullane, D.O., Karl Weiss, Arnold Lentnek, Yoav Golan, Sherwood Gorbach, M.D., Pamela Sears, Youe-Kong Shue. *N Engl J Med* 2011; 364:422-431
- [37] Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. *Infect Control Hosp Epidemiol*. 2003;24:699-706.

- [38] Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of *Clostridium difficile*-associated diarrhea and cost. *Ann Intern Med*. 1998;128(12 pt 1):989-95.
- [39] Prevention of Endemic Healthcare-Associated *Clostridium difficile* Infection: Reviewing the Evidence. J Hsu, C Abad, M Dinh, N Safdar. *Am J Gastroenterol* 6 July 2010; doi: 10.1038/ajg.2010.254
- [40] Leischner J, Johnson S, Sambol S, Parada J, Gerding DN. Effect of alcohol hand gels and chlorhexidine hand wash in removing spores of *Clostridium difficile* from hands [abstr]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005:LB-29.

IntechOpen



Current Concepts in Colonic Disorders

Edited by Dr. Godfrey Lule

ISBN 978-953-307-957-8

Hard cover, 276 pages

Publisher InTech

Published online 05, January, 2012

Published in print edition January, 2012

The 21st Century has seen a resurgence of research of the gastrointestinal tract, especially since it was established that it plays a central role as an immune system organ and consequentially has a huge impact on causation, impact and transmission of most human ailments. New diseases such as the Acquired Immunodeficiency Syndrome, hepatitis and tumours of the gastrointestinal tract have emerged and they are currently subjects of intensive research and topics of scientific papers published worldwide. Old diseases like diarrhea have become extremely complex to diagnose with new and old pathogens, drugs, tumours and malabsorptive disorders accounting for the confusion. This book has set out algorithms on how to approach such conditions in a systematic way both to reach a diagnosis and to make patient management cheaper and more efficient. "Current Concepts in Colonic Disorders" attempts to put all the new information into proper perspective with emphasis on aetiopathogenesis and providing rational approach to management of various old and new diseases. As the book editor, I have found this first edition extremely interesting and easy to understand. Comments on how to improve the content and manner of presentation for future editions are extremely welcome.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Enoch Lule (2012). Clostridia Difficile Diarrhea, Current Concepts in Colonic Disorders, Dr. Godfrey Lule (Ed.), ISBN: 978-953-307-957-8, InTech, Available from: <http://www.intechopen.com/books/current-concepts-in-colonic-disorders/clostridia-difficile-diarrhea>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen